Common Contracts
2 similar Exclusive Patent License Agreement contracts by Sigilon Therapeutics, Inc.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. FIRST AMENDMENTExclusive Patent License Agreement • November 13th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (“Amendment”), effective as of February 2, 2017, amends the Exclusive Patent License Agreement (the “Agreement”) dated February 8, 2016 by and between Sigilon, Inc. (“Sigilon”) and the Massachusetts Institute of Technology (“M.I.T.”). Capitalized terms not defined herein shall have the meaning assigned to them in the Agreement.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. FIRST AMENDMENTExclusive Patent License Agreement • August 21st, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment (“Amendment”), effective as of February 2, 2017, amends the Exclusive Patent License Agreement (the “Agreement”) dated February 8, 2016 by and between Sigilon, Inc. (“Sigilon”) and the Massachusetts Institute of Technology (“M.I.T.”). Capitalized terms not defined herein shall have the meaning assigned to them in the Agreement.
